Testimonials: Advancing Drug Discovery with AI & Data-Driven Innovation
At PozeSCAF Inc., we are revolutionizing drug discovery through our AI-powered platform – AxDrug and data-driven insights. Our expertise spans small molecule design, PROTACs, Molecular Glues, and custom synthesis, helping biopharma companies accelerate innovation from early-stage discovery to preclinical development.
Our clients and collaborators recognize our commitment to scientific excellence and cutting-edge technology. Here’s what they have to say about working with us:
What Our Clients Say
1. AI Drug Discovery and synthesis
My laboratory has had a productive and positive collaboration with PozeSCAF on an early-stage small-molecule discovery project. PozeSCAF’s team has demonstrated strong scientific expertise, thoughtful AI-enabled compound prioritization, and a practical understanding of how computational approaches can support experimental drug discovery.
Their deliverables have been clear, timely, and actionable, and the team has been highly responsive to feedback and experimental results. I have especially appreciated their collaborative style, scientific curiosity, and willingness to refine hypotheses as the project evolves.
Based on our experience, PozeSCAF has been a valuable drug discovery partner, combining computational insight with a collaborative and experimentally grounded approach.
This statement reflects my personal experience as a scientific collaborator, and does not represent an institutional endorsement.
Jeff Perry, Ph.D. – Assistant Professor, Department of Cancer Biology and Molecular Medicine, Beckman Research Institute of City of Hope
The Perry Lab focuses on elucidating the structural and mechanistic basis of genome maintenance, DNA repair and signal transduction pathways, with the goal of translating these insights into novel chemical tools and therapeutic strategies. By leveraging structure-guided approaches together with rigorous biophysical and biochemical validation, his work aims to identify and exploit vulnerabilities in disease-relevant protein hubs that regulate key cellular pathways, enabling the development of next-generation small-molecule therapeutics. Dr. Perry has authored more than 60 peer-reviewed publications and is an inventor on multiple patents in these areas.
1500 East Duarte Road
Duarte, CA 91010
Date: June 01, 2026
2. AI Drug Discovery and synthesis
I have had the opportunity to work with PozeSCAF Inc. on computational drug discovery and medicinal chemistry-related projects and have been very impressed with the quality of the scientific support, responsiveness, and collaborative approach demonstrated by the team.
PozeSCAF brings together strong expertise across AI-driven molecular design, computational chemistry, medicinal chemistry, and integrated drug discovery workflows. Throughout our interactions, the team has consistently been thoughtful, technically strong, and highly committed to supporting project goals and timelines.
One aspect I particularly appreciated was the ability of the PozeSCAF team to engage scientifically at a deep level while also maintaining flexibility and speed in execution. Communication was always professional and collaborative, and the team was proactive in discussions, problem-solving, and incorporating feedback.
Our experience working with PozeSCAF to design novel drugs targeting innovative therapeutic targets to treat cancer has been very positive with excellent and transparent communications and sharing of information.
I would be happy to recommend them as a capable and collaborative partner for AI-enabled drug discovery and related scientific programs.
Guru P. Sonpavde, MD serves as the Medical Director of Genitourinary (GU) Oncology, Assistant Director of the Clinical Research Unit and Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute
Previously, he was Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School from 2017-2022, GU Oncology Director and Associate Professor of Medicine at the University of Alabama at Birmingham from 2012 to 2017 and practiced from 2004 to 2012 at Texas Oncology. His focus is drug development and translational research to cure GU cancers, which have led to approximately 500 publications. He is a member of Southwest Oncology Group, Scientific Advisory Board of the Bladder Cancer Advocacy Network (BCAN), and the Bladder Cancer Task Force of U.S. NCI GU Steering Committee.
Orlando, USA
Date: May 07, 2026
3. AI-Driven Small Molecule Discovery & Synthesis
“Our collaboration with PozeSCAF, which began in 2019, has been outstanding. By leveraging their AI-powered AxDrug platform and extensive computational chemistry expertise, we have successfully advanced multiple small molecule drug discovery projects. Their end-to-end capabilities, from AI-driven molecular design to synthesis services, have significantly accelerated our research timelines. The PozeSCAF team is highly receptive, demonstrates scientific excellence, and maintains a strong partnership approach, making them a trusted ally in our discovery efforts. We look forward to continuing this successful collaboration.”
Mohan R. Kaadige, PhD
Research Associate Professor
Translational Genomics Research Institute, part of City of Hope
Phoenix, AZ, USA
Date: February 10, 2025
4. AI-driven PROTACs design and synthesis
At Tuskegee University, we had the privilege of collaborating with PozeSCAF Inc. for our small molecule discovery needs, particularly in the hit-to-lead optimization phase and the design and evaluation of PROTACs.
PozeSCAF’s expertise in AI-driven drug discovery, computational chemistry, and synthetic chemistry was instrumental in accelerating our research. Their AxDrug platform provided deep computational insights, facilitating efficient hit identification, SAR analysis, and lead optimization. By integrating structure-based design, FEP-based ranking, and in silico ADMET prediction, we were able to prioritize the most promising candidates for synthesis with greater precision.
The PozeSCAF team demonstrated a strong understanding of the complexities of PROTAC development, including linker optimization and target engagement. Their synthesis capabilities and iterative design approach enabled us to advance key molecules efficiently, optimizing resource use while enhancing the probability of success.
Our partnership with PozeSCAF has been invaluable in streamlining our small molecule pipeline. Their combination of cutting-edge AI technology and medicinal chemistry expertise makes them an excellent partner for companies engaged in small molecule drug discovery and PROTAC development.
With bi-weekly interactions, our collaboration has been seamless, ensuring clear communication and steady progress. PozeSCAF’s responsiveness, scientific expertise, and commitment to excellence have made this partnership highly effective.
We appreciate PozeSCAF’s professionalism, transparency, timely deliverables, and scientific rigor and look forward to continued collaboration in the future.
Balu Karanam Ph.D
Associate Professor
Department of Biology and Cancer Research
Tuskegee University
Tuskegee, AL, USA
Date: February 10, 2025
5. Custom Synthesis
I had the opportunity to collaborate with PozeSCAF on synthesizing small molecules for our
upcoming product development, and I was impressed with their expertise, professionalism,
and commitment to quality. The team ensured timely delivery, seamless communication, and
a high standard of work, making our experience highly positive.
I look forward to future collaborations with them and would highly recommend their services
to others in the industry.
Manush Saydmohammed, Ph.D., MBA
Co-Founder & CEO
Zegenex Inc
Pittsburgh, PA, USA
Date: February 10, 2025